New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Leerink raised its price target yesterday for shares of Alkermes to $66 after the company reported positive top-line aripiprazole lauroxil Phase III data. The firm expects FDA approval and launch in Q3 of 2015 and reiterates an Outperform rating on the stock.
News For ALKS From The Last 14 Days
Check below for free stories on ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
07:12 EDTALKSCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
August 26, 2014
07:05 EDTALKSAlkermes initiates Phase 1 clinical study of ALKS 7106 for treatment of pain
Subscribe for More Information
August 25, 2014
07:01 EDTALKSAlkermes submits NDA to FDA for aripiprazole lauroxil
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use